To optimize the therapeutic value of an operation for cancer, surgeons must weigh survival value against mortality/morbidity risk. As a result of several prospective, randomized trials, many surgeons feel that international opinion has reached a consensus. Reflexively radical surgical hubris has certainly given way to a more nuanced, customized approach to this disease. But issues remain. This article critically reviews existing data and emphasizes areas of continued controversy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2011.09.005 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!